Web-only files

[1] MEDLINE search strategy

Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to 24 May 2012

1. bevacizumab.mp.
2. avastin.mp.
3. 1 or 2
4. ae.fs.
5. to.fs.
6. po.fs.
7. or/4-6
8. 3 and 7
9. (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$).ti,ab.
10. 8 not 9
11. ((side or adverse or undesirable) adj2 (event$ or effect$ or reaction$ or outcome$)).ab,ti.
12. adrs.ab,ti.
13. (safe or safety).ab,ti.
15. tolerability.ab,ti.
16. toxicity.ab,ti.
17. or/11-16
18. 3 and 17
19. (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$).ti,ab.
20. 18 not 19
21. exp Endophthalmitis/ci
22. endophthalmiti$.ab,ti.
23. (intraocular adj2 (pressure$ or tension$)).ab,ti.
24. hypotony.ab,ti.
25. exp Cataract/ci
26. cataract$.ab,ti.
27. Retinal Detachment/ci
29. exp Retinal Artery Occlusion/ci [Chemically Induced]
30. retina$ artery occlu$.ab,ti.
31. crao.ab,ti.
32. vitreoretinal fibros$.ab,ti.
33. discomfort.ab,ti.
34. pain.ab,ti.
35. corneal abrasion.ab,ti.
36. lens injur$.ab,ti.
37. Uveitis/ci [Chemically Induced]
38. uveitis.ab,ti.
39. infection$.ab,ti.
40. itch$.ab,ti.
41. (vision adj2 (loss or reduced or subnormal or diminished or abnormal)).ab,ti.
42. (subconjunctival adj (haemorrhag$ or hemorrhag$)).ab,ti.
43. ((subretinal or retina$) adj (haemorrhag$ or hemorrhag$)).ab,ti.
44. (retina$ adj3 tear$).ab,ti.
45. rpe tears.ab,ti.
46. blood pressure.ab,ti.
47. Venous Thrombosis/ci [Chemically Induced]
48. Ischemic Attack, Transient/ci [Chemically Induced]
49. Stroke/ci [Chemically Induced]
50. Myocardial Infarction/ci [Chemically Induced]
51. Death/
52. or/21-51
53. 3 and 52
54. (cancer$ or neoplas$ or oncol$ or malignan$ or tumo?$ or carcinoma$ or adenocarcinoma$).ti,ab.
55. 53 not 54
56. 10 or 20
57. 55 or 56
58. limit 57 to yr="2009 -Current"
Quality assessment of included randomised controlled trials

| Author, year | Methodological assessment criteria
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ahmadieh 2008¹</td>
<td>Y Y U Y Y U Y Y U U</td>
</tr>
<tr>
<td>Bashshur 2007²</td>
<td>U U U U Y U Y Y U U</td>
</tr>
<tr>
<td>Biswas 2011³</td>
<td>U U U U Y U Y U U</td>
</tr>
<tr>
<td>CATT 2012⁴</td>
<td>Y Y Y Y Y Y Y Y Y</td>
</tr>
<tr>
<td>Cekic 2010⁵</td>
<td>U U U Y U Y U U U</td>
</tr>
<tr>
<td>Ding 2011⁶</td>
<td>U U N N U Y U U</td>
</tr>
<tr>
<td>DRCRN 2007⁷</td>
<td>U U N Y Y Y Y U U</td>
</tr>
<tr>
<td>Epstein 2012⁸</td>
<td>Y Y Y Y Y Y Y Y U U</td>
</tr>
<tr>
<td>Faghihi 2008⁹</td>
<td>Y U U Y U U U N U</td>
</tr>
<tr>
<td>Gharbiya 2009¹⁰</td>
<td>U U U Y U U U N U</td>
</tr>
<tr>
<td>IVAN 2012¹¹</td>
<td>Y Y Y Y Y Y Y Y U U</td>
</tr>
<tr>
<td>Lazic 2007¹²</td>
<td>Y U N N Y U U U</td>
</tr>
<tr>
<td>Lim 2012¹³</td>
<td>Y Y U Y U Y Y U U</td>
</tr>
<tr>
<td>Marey 2011¹⁴</td>
<td>U U U U U U N U U</td>
</tr>
<tr>
<td>Michaelides 2010¹⁵</td>
<td>Y Y N Y Y U Y U U</td>
</tr>
<tr>
<td>Moradian 2011¹⁶</td>
<td>Y U U Y U Y U U U</td>
</tr>
<tr>
<td>Patwardhan 2011¹⁷</td>
<td>Y U U U U U U U</td>
</tr>
<tr>
<td>Schmid-Kubista 2011¹⁸</td>
<td>Y U Y Y Y U Y U U</td>
</tr>
<tr>
<td>Shahin 2010¹⁹</td>
<td>U U U U U U U U U</td>
</tr>
<tr>
<td>Sohelian 2012²⁰</td>
<td>Y Y Y Y U U U U U</td>
</tr>
<tr>
<td>Tufail 2010²¹</td>
<td>U U U Y Y U U U</td>
</tr>
<tr>
<td>Yazdani 2009²²</td>
<td>Y Y N U U Y U U U</td>
</tr>
</tbody>
</table>

¹Y, yes (low risk of bias); N, no (high risk of bias); U, unclear (insufficient detail to assess quality item)

1: Was assignment to treatment groups truly random?
2: Was treatment allocation adequately concealed?
3: Were patients and investigators blinded to treatment allocation?
4: Were outcome assessors blinded to treatment allocation?
5: Was follow-up of patients adequate (at least 80%)?
6: Was the study free from selective outcome reporting?
7: Was follow-up time sufficient to assess safety outcomes?
8: Were expected adverse events defined or described adequately?
9: Were methods for assessing expected adverse events defined or described?
10: Were safety outcomes validated?
Bibliography


